Valye reports for unlimited access

First America Resources Corporation, incorporated in 2010 and headquartered in Morris, Illinois, operates primarily through its subsidiary METech Recycling, which has a long history in precious metal recovery and electronics recycling. The company provides IT asset disposition services including refurbishment, resale, secure data destruction, and electronics recycling. It also offers specialized services for AI infrastructure lifecycle management and data center decommissioning. The company handles a broad range of IT and electronic products, including emerging technology equipment such as solar panels and electric vehicle batteries. It serves a diverse customer base across technology, telecommunications, defense, education, and government sectors, including Fortune 500 companies. The company leverages internally developed and third-party software systems with AI and machine learning to enhance operational efficiency, asset classification, and pricing. Facilities are located across several U.S. states, supporting logistics and processing activities. The company maintains environmental compliance programs and holds R2v3 Responsible Recycler certification. Financially, the company reported revenues of $18.79 million and a net income of $2,765 for the fiscal year ending December 31, 2025, with liquidity ratios indicating some working capital constraints.

Aura Minerals Inc. is a mining company focused on gold and copper production in the Americas, operating six wholly-owned mines in Honduras, Brazil, and Mexico. The company pursues growth through acquisitions, mine expansions, and operational improvements, emphasizing sustainability and efficient capital deployment. Key operating mines include Minosa, Almas, Apoena, Borborema, MSG, and Aranzazu. Development projects include Matupá in Brazil, which features detailed mineral resource and reserve estimates prepared under S-K 1300 standards. The company reported significant revenue growth in 2025 driven by higher metal prices and production from new mines. Aura Minerals manages a diversified customer base for its gold and copper products and maintains a disciplined approach to capital expenditures and debt management.

Aura Minerals Inc. is a gold and copper mining company with operations primarily in the Americas, including Honduras, Brazil, Mexico, and Guatemala. The company operates six wholly-owned mines and is developing several projects, including the Matupá Gold Project in Brazil. Aura Minerals emphasizes operational efficiency, sustainable mining practices, and disciplined capital allocation to generate cash flow and dividends. The company holds extensive mineral rights and actively pursues exploration to expand its resource base. Its processing facilities employ advanced metallurgical techniques such as carbon-in-leach and cyanide detoxification. Financially, Aura Minerals reported significant revenue growth in 2025 driven by higher metal prices and production from new mines, alongside increased capital expenditures for project development. The company manages debt with various financial covenants and collateral arrangements and maintains relationships with major customers for gold and copper concentrate sales [S1][S2].

MicroAlgo Inc. develops and applies bespoke central processing algorithms integrated with software and hardware to optimize digital services, primarily serving the internet multimedia video advertising sector. The company’s services include algorithm optimization, accelerating computing power without hardware upgrades, lightweight data processing, and data intelligence services. Historically, revenue was also generated from intelligent chips and services, but this segment was discontinued after 2023. The company’s revenue has declined in recent years due to market demand shifts and economic uncertainty, with a focus on maintaining profitability and operational efficiency. MicroAlgo is expanding its technology applications into quantum information systems and combinatorial optimization algorithms, aiming to broaden its customer base beyond advertising into finance, retail, logistics, and other industries. The company maintains strong liquidity and has completed convertible note issuances converted into equity to support operations and debt repayment.

Innate Pharma SA is a French clinical-stage biotechnology company focused on developing innovative immunotherapies that harness the innate immune system to treat cancer. The company’s therapeutic approaches include monoclonal antibodies, multispecific NK Cell Engagers via its proprietary ANKET® platform, and Antibody Drug Conjugates (ADC). Its pipeline features proprietary programs such as lacutamab for cutaneous and peripheral T cell lymphomas, monalizumab developed in collaboration with AstraZeneca for non-small cell lung cancer, and several ANKET® candidates targeting various tumor types. Innate Pharma maintains strategic collaborations and licensing agreements with major pharmaceutical companies including AstraZeneca, Sanofi, and Takeda, which provide upfront payments, milestone payments, and research funding. The company’s revenue primarily derives from these collaborations and government research financing. Financially, Innate Pharma reported €9.0 million in revenue and a net loss of €49.2 million for the fiscal year ended December 31, 2025. The company held €28.1 million in cash and equivalents and had a current ratio of 1.27 at year-end 2025. Liquidity is sufficient to fund operations through the third quarter of 2026, with additional financing needed thereafter. The company has incurred net losses historically due to research and development and administrative expenses. Recent developments include FDA breakthrough therapy designation for lacutamab and workforce reductions to manage costs.

ASE Technology Holding Co., Ltd. operates as a leading semiconductor manufacturing services company specializing in assembly and testing. Its business segments include Advanced Technology Manufacturing (ATM), covering packaging and testing, and Electronic Manufacturing Services (EMS). The company offers turnkey solutions including front-end engineering test, wafer probing, final test, packaging, materials, and EMS products. ASE has a global presence with manufacturing and R&D facilities across Asia, the Americas, and Europe. The company focuses on advanced packaging technologies such as BGA, SiP, and high-frequency testing solutions, collaborating closely with substrate suppliers and customers to enhance production capabilities and technology adoption. ASE reported consolidated revenues of approximately US$20.57 billion and net income of about US$1.31 billion for the fiscal year ended December 31, 2025. The company maintains a strong liquidity position with a current ratio of 1.26 and cash ratio of 0.37 as of the same date. ASE invests significantly in research and development, dedicating over 14,000 employees and allocating over 5% of revenues to R&D activities. The company’s dividend policy includes cash dividends of not less than 30% of total dividends, with residual dividends paid in stock, subject to earnings and legal reserve requirements. ASE’s customer base is concentrated, with the top five customers accounting for about 41% of net revenues in packaging and testing segments and about 70% in EMS. The company actively manages foreign currency exchange risks through hedging instruments. ASE’s shares trade on the Taiwan Stock Exchange and its ADSs on the NYSE.

Scinai Immunotherapeutics Ltd. is an Israeli biopharmaceutical company with two complementary business units: a research and development (R&D) segment focused on inflammation and immunology therapeutics, and a contract development and manufacturing organization (CDMO) segment operating through its subsidiary Scinai Biopharma Services Ltd. The R&D unit is developing a pipeline based on NanoAbs (nanosized antibody fragments) and the PC111 monoclonal antibody program, collaborating with leading academic institutions such as the Max Planck Society and University Medical Center Göttingen. The CDMO business provides integrated development and cGMP manufacturing services for early-stage biotech clients, supported by facilities in Jerusalem and Yavne, Israel, following the acquisition of Recipharm Israel Ltd. in February 2026. The company has a history of clinical trials, including a large phase 3 trial for a universal influenza vaccine candidate that did not meet endpoints, prompting a strategic refocus. Financially, the company reported revenues of $1.31 million and a net loss of $8.3 million for the year ended December 31, 2025, with liquidity constraints noted. The company continues to raise capital through equity offerings and grants to support operations and growth.

Aegon Ltd. operates as a global financial services holding company offering investment, protection, and retirement products. Its portfolio includes fully owned businesses in the US and UK, a global asset manager, insurance joint ventures in multiple countries, and strategic shareholdings. Headquartered in the Netherlands and domiciled in Bermuda, Aegon is listed on major exchanges. The company reported EUR 21.3 billion revenue in 2022 and EUR 980 million net income in 2025. It manages capital through share buybacks and strategic asset management, with a focus on sustainability and ESG integration. Aegon is in the process of relocating its legal domicile and head office to the US and plans to rename as Transamerica. The CEO's term extension reflects a focus on leadership continuity during this transformation.

Aura Minerals Inc. is a gold and copper mining company with operations across the Americas, including six wholly-owned mines in Honduras, Brazil, and Mexico. The company pursues growth through strategic acquisitions, mine expansions, and operational efficiencies, emphasizing sustainable mining practices and disciplined capital allocation. Key development projects include the Matupá Gold Project in Brazil, which features advanced processing facilities and significant mineral reserves and resources. Aura Minerals reported strong revenue growth in 2025 driven by higher metal prices and increased production from new mines. The company maintains a diversified customer base and manages financial obligations through loans, debentures, and credit facilities with established covenants. Exploration activities continue to support resource expansion near existing projects.

TOYO Co., Ltd operates in the solar energy sector, manufacturing solar cells and modules and providing facilitation and OEM services. The company has a single operating segment and generates most of its revenue from the USA, with additional operations in Vietnam, Singapore, Ethiopia, China, and Japan. TOYO has expanded its US manufacturing capacity through acquisition of Solar Plus Technology Texas LLC and commissioning of a 1GW solar module plant in Houston, Texas. The company has a concentrated customer base, with a few customers accounting for a large portion of revenues and accounts receivable. TOYO's financials show growth in revenues and profitability over recent years but also highlight liquidity challenges with significant working capital deficits and reliance on financing from related parties and investors. The company recognizes revenue primarily in US Dollars, with some subsidiaries operating in local currencies subject to foreign exchange controls. Recent leadership changes bring experienced management focused on energy infrastructure and decarbonization.

A2Z Cust2Mate Solutions Corp. is an innovative technology company incorporated in Canada with operational offices in Israel and a U.S. subsidiary. The company develops and commercializes retail smart cart solutions (Cust2Mate Products) designed for large grocery stores and supermarkets, manufactures precision metal parts, provides maintenance services in Israel, and develops vehicle safety technology. Since 2020, the company has focused on expanding its smart cart business, which features mobile self-checkout carts equipped with touch screens, proprietary software, and anti-fraud technologies. The smart carts enable real-time item scanning, mobile payments, and digital advertising services. The company generates revenue through upfront fees and recurring monthly subscriptions under multiyear agreements, supplemented by a retail media platform that monetizes advertising and commissions. Key customers include large Israeli retailers such as Yochananof and Super Sapir, with strategic partnerships for deployment in France, Mexico, and Central America. The company reported $7.9 million in revenue for 2025, with 41% from smart carts and 59% from precision metal parts. Despite recurring net losses, the company maintains a strong liquidity position and continues to invest in research and development to support growth.

Capstone Companies, Inc. was historically engaged in designing, promoting, and licensing consumer products aimed at simplifying daily living through technology. Its most recent product, the Connected Chef kitchen tablet, was not successfully commercialized in 2025, leading to termination of its licensing agreement. The company ceased promotion of its LED Lighting product line in 2023 and ended the Smart Mirror product line in 2024 due to poor sales. In 2024 and 2025, Capstone pursued development of a new business line in the health, fitness, and social activities (HFS) industry but did not acquire or develop any operations by the end of 2025. The company relies on unsecured promissory notes from related parties, including Coppermine Ventures LLC and eBliss Global, for working capital. As of late 2025 and early 2026, Capstone has no revenue-generating business or products in active commercialization and faces significant liquidity constraints and going concern risks.

Generation Income Properties, Inc. is a publicly traded company listed on The Nasdaq Stock Market under the ticker GIPR. The company operates in real estate, having sold office and retail properties in late 2025. It reported revenue of approximately $9.74 million and a net loss of approximately $10.34 million for the fiscal year ended December 31, 2025. The company holds cash and cash equivalents of approximately $6.16 million as of the same date. It has faced Nasdaq listing compliance challenges, including a minimum bid price deficiency, and has engaged in appeals and strategic reviews to address these issues. Leadership changes and a consulting agreement were announced in early 2026, alongside the conclusion of a special committee's review of strategic alternatives.

Genenta Science S.p.A. operates as a clinical-stage biotechnology company focused on developing gene therapies for solid tumors using a novel platform that modifies hematopoietic stem/progenitor cells to deliver immunomodulatory molecules to tumors via Tie2 Expressing Monocytes (TEMs). The technology aims to treat a broad range of cancers by leveraging the natural tumor-homing properties of TEMs. The company has no approved products or commercial revenue and has historically funded operations through equity and convertible debt financings. It is undergoing a strategic transformation to become an industrial consolidator acquiring majority stakes in privately held Italian companies within national-security regulated sectors under Italy's Golden Power legislation, including biotechnology, defense, aerospace, cybersecurity, and related fields. This strategy involves acquiring companies with established profitability and integrating them to enhance operational and financial performance. Genenta has recently entered a binding offer to acquire a majority stake in Sòphia High Tech, an aerospace and defense engineering firm, as part of this transformation. The company maintains strong liquidity with cash and marketable securities totaling approximately €28.1 million as of December 31, 2025, and continues to invest in research and development of its gene therapy candidates while managing operating expenses.

Idea Acquisition Corp. is a Cayman Islands-incorporated special purpose acquisition company (SPAC) that completed its IPO in February 2026, raising $350 million through the issuance of units consisting of Class A ordinary shares and redeemable warrants. The company simultaneously completed a private placement of warrants to its sponsor and underwriters. The proceeds from these offerings are held in a trust account with restrictions on their release until the completion of an initial business combination or other specified events. As of the fiscal year ended December 31, 2025, the company reported no cash on hand, current liabilities of approximately $365,000, and a net loss of $48,912. The company has not disclosed any revenue or operational details, consistent with its status as a SPAC prior to a business combination.

Universal Token, Inc. is a financial technology company incorporated in Wyoming in 2021, focused on developing an open-source blockchain platform (UTKN) for tokenizing real-world assets (RWA), such as commodities like gold. The platform is designed to enable secure transfer of digital assets across wallets with comprehensive KYC and AML processes. The company targets central and local banks for platform integration, involving backend programming and currency conversions. Custody of tokens remains with customers. Universal Token is in the process of obtaining regulatory licenses in El Salvador and plans to expand licensing to other countries including UAE and Thailand. The company has limited operational scale with one full-time employee and one part-time CTO, and its corporate offices are in El Salvador with operations across Central America and Asia. Financially, the company reported no revenue and a net loss for the fiscal year ending December 31, 2025, with current liabilities exceeding current assets [S1].

PAID INC offers a comprehensive platform for small and medium businesses to establish and manage e-commerce operations, including website creation, payment processing, multi-channel sales management, and shipping coordination. Its PaidCart, PaidPayments, and PaidShipping products integrate to provide a seamless experience from online sales to delivery. The company leverages partnerships with leading carriers to offer discounted shipping rates and multi-courier comparison tools. It actively markets to small businesses and partners with associations, particularly in Canada. Recent operational focus has been on expanding shipping coordination services amid shifts in carrier usage.

Crown PropTech Acquisitions is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in 2020. Its sole purpose is to identify and complete a business combination with one or more target companies. The company completed its initial public offering in February 2021, raising gross proceeds of $276 million, which were placed in a Trust Account invested in U.S. government securities. The company has not generated any operating revenues and has incurred net losses related to operating costs and expenses associated with being a public company and pursuing a business combination. It is currently engaged in a proposed business combination with Mkango Rare Earths Limited and related entities, with the agreement amended to extend the deadline for completion to September 30, 2026, with a possible extension to December 31, 2026. The company’s financial position as of December 31, 2025, shows a working capital deficit and limited cash outside the Trust Account, with the Trust Account funds restricted for use in the business combination or shareholder redemptions.

ENDRA Life Sciences Inc. focuses on developing and commercializing Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology, which aims to improve ultrasound imaging quality and diagnostic capabilities. The company’s product portfolio includes devices targeting liver imaging applications, such as the MASLD TAEUS device and the TAEUS FLIP System. ENDRA has obtained CE mark approval for marketing in the European Union and is pursuing FDA regulatory clearance in the United States through a de novo classification process. The company relies on third-party manufacturers and is building sales and marketing capabilities to support commercialization. ENDRA also explores opportunities in digital assets and cryptocurrency as part of its portfolio expansion. The company has a history of operating losses and requires additional capital to support ongoing development and commercialization efforts.

Nuburu, Inc. specializes in high-powered blue laser technology products and related installation services. The company serves customers primarily in the United States, Europe, and Asia. Revenue recognition follows standard accounting principles, with product sales recognized at a point in time and installation services recognized over time. Despite historical revenue generation, Nuburu did not record revenue in 2025 and continues to operate at a net loss, reflecting its developmental stage and ongoing commercialization efforts. The company has taken cost reduction measures including employee furloughs, which have impacted operations. Nuburu is actively pursuing strategic initiatives including acquisitions, joint ventures, and investments to expand its technology applications, especially in defense and security sectors. It has also engaged in multiple financing activities to support its operations and growth plans. The company faced a trading halt due to low stock price but implemented a reverse stock split to regain compliance with NYSE American listing standards. It is currently under a compliance plan with the exchange.

Alpha Cognition Inc. operates as a biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company’s flagship product, ZUNVEYL (benzgalantamine), is a next-generation acetylcholinesterase inhibitor approved by the FDA in July 2024 and commercially launched in March 2025. ZUNVEYL is designed to provide symptomatic relief for mild to moderate Alzheimer's disease with a differentiated mechanism and improved tolerability profile, particularly minimizing gastrointestinal side effects. The company targets the long-term care market in the U.S., leveraging a specialty sales force and engaging with Medicare payors and pharmacy benefit managers to expand formulary coverage. Alpha Cognition also pursues pre-clinical development of additional formulations and combination therapies, including sublingual ALPHA-1062 for mild traumatic brain injury and combination with memantine for moderate-to-severe Alzheimer's disease. The company maintains strong liquidity with $66 million in cash and equivalents as of year-end 2025 but has incurred significant net losses since inception. It faces competition from established symptomatic treatments and emerging disease-modifying therapies but aims to differentiate through clinical benefits and tolerability.

Edible Garden AG Inc operates in the indoor agriculture and consumer packaged goods sectors, focusing on fresh produce and sustainable agriculture products. The company sells primarily to national and local supermarket chains, with a high concentration of revenue from a few customers. It owns or controls growing facilities in Michigan and New Jersey and uses third-party contract growers. The company has developed proprietary forecasting software (GreenThumb) to manage supply and demand. Recent strategic initiatives include launching new product lines such as Pickle Party™, Pulp®, and Kick. Sports Nutrition, expanding distribution through major retailers, acquiring NaturalShrimp assets, and developing a ready-to-drink beverage manufacturing platform at its Iowa facility. The company has a history of significant net losses and liquidity challenges, with auditors expressing substantial doubt about its ability to continue as a going concern. Edible Garden faces competitive pressures, low industry margins, customer concentration risks, and environmental risks related to weather and climate change.

Alset Inc. is a diversified holding company engaged through subsidiaries in real estate development, digital transformation technologies, biohealth activities, and consumer products. Its operations span the United States, Singapore, Hong Kong, Australia, South Korea, and China. The company manages its principal businesses primarily through its 85.8% owned subsidiary, Alset International Limited, publicly traded on the Singapore Stock Exchange. The real estate segment focuses on land subdivision developments near Houston, Texas, including the Lakes at Black Oak project and the Alset Villas community, with a portfolio of 132 single-family rental homes equipped with smart home and solar technologies. The digital transformation technology segment provides B2B solutions in e-commerce, collaboration, social networking, and incorporates advanced technologies such as AI and metaverse services. The biohealth segment develops, manufactures, licenses, and distributes health-related products, with operations in Korea and the US. The company completed the acquisition of New Energy Asia Pacific Inc. in 2025, expanding into the distribution of all-electric special-purpose and transportation vehicles, charging stations, and batteries. Alset Inc. reported revenue of approximately $4.5 million and a net loss of about $47.4 million for the fiscal year ended December 31, 2025, with strong liquidity ratios indicating a solid short-term financial position. The company operates with a holding company structure and depends on earnings and distributions from its subsidiaries to meet obligations. It faces competitive and operational risks and is actively managing a material weakness in internal controls related to staffing.[S1][S2]

Fortress Biotech, Inc. operates as a biopharmaceutical company through a network of subsidiaries and partner companies engaged in the development and commercialization of pharmaceutical products across various therapeutic areas. The company provides business, scientific, regulatory, legal, and financial support to its subsidiaries, which include publicly traded entities such as Journey Medical Corporation, Mustang Bio, and Avenue Therapeutics, as well as private subsidiaries. Fortress's business model centers on acquiring or licensing intellectual property and advancing product candidates through development, regulatory approval, and commercialization. The company generates revenue primarily through product sales by its subsidiaries, collaboration agreements, and milestone payments. Fortress also raises capital through equity and debt offerings, warrant exercises, and asset sales to fund operations and growth initiatives. The company maintains contractual arrangements with specialty pharmacies and commercial payers, including rebates and product return policies consistent with industry standards. Fortress's consolidated financial position as of December 31, 2025, reflects total assets of approximately $185.5 million and stockholders' equity of $62.2 million, supported by liquidity measures indicating operational funding sufficiency for at least 12 months post-filing.

Decoy Therapeutics Inc. is a biotechnology company at the pre-clinical stage, specializing in peptide conjugate therapeutics engineered through its proprietary IMP 3 ACT™ platform. This platform leverages machine learning and artificial intelligence alongside fast-flow synthesis to rapidly design and manufacture peptide conjugates targeting serious unmet medical needs, primarily in infectious diseases and oncology. The company emerged from a merger completed in November 2025 between Salarius Pharmaceuticals and Legacy Decoy, resulting in a combined entity renamed Decoy Therapeutics Inc. in January 2026. The merger integrated complementary drug development approaches, including legacy small molecule clinical candidates and the novel peptide conjugate platform. The company has no approved products or revenues and is advancing multiple drug development programs, including a lead pan-Coronavirus antiviral prophylactic targeting immunocompromised patients, supported by significant non-dilutive funding. It plans to file an IND application in the first half of 2027 and is pursuing strategic partnerships and platform manufacturing capabilities. The company maintains Nasdaq listing compliance through reverse stock splits and regulatory appeals and reported a net loss of $12.5 million for the year ended December 31, 2025, with cash and equivalents of approximately $10.7 million.

Kodiak Sciences Inc. develops next-generation retinal therapeutics using its proprietary Antibody Biopolymer Conjugate (ABC) platform. Founded in 2009, the company focuses on preventing and treating major causes of blindness through biologic therapies with enhanced durability and efficacy. Its lead product candidate, tarcocimab tedromer (Zenkuda), is an anti-VEGF therapy designed for extended ocular half-life and flexible dosing intervals from 1 to 6 months. Kodiak has completed multiple Phase 3 studies demonstrating efficacy in diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration, with ongoing pivotal trials. Additional candidates include KSI-501, a bispecific anti-IL-6/VEGF therapy, and KSI-101 targeting inflammation-related macular edema. The company has invested in commercial-scale manufacturing capabilities and retains global commercialization rights. Kodiak is in the clinical stage with no approved products and has incurred significant net losses since inception.

Femasys Inc. is a medical device company specializing in women-specific medical products, including non-surgical permanent birth control and intratubal insemination solutions. The company has expanded its commercial presence in Europe through partnerships and has received regulatory certifications such as the CE Mark for its FemBloc system. Femasys has raised capital through public offerings to support product development and commercialization efforts. The company reported a net loss for the year ended December 31, 2025, and maintains liquidity with a current ratio above 4. It faces Nasdaq listing compliance challenges related to minimum bid price and market value requirements, with ongoing efforts to address these issues.

ADM Endeavors, Inc., through its subsidiary Just Right Products, operates a diverse vertically integrated business focused on promotional products and uniforms. The company offers a wide range of logoed products via retail sales, screen printing, embroidery, digital production, and import wholesale sourcing. It serves various customers including government entities, businesses, schools, and municipalities. The company has expanded its government contracts significantly and has developed a strong online presence supported by SEO and web marketing. In 2025, ADM Endeavors completed construction of a new corporate headquarters and production facility in Fort Worth, Texas, which expands production capacity by up to 5.8 times and supports fulfillment services. The company is navigating industry challenges such as tariffs affecting the school uniform market by sourcing its own branded uniforms and capitalizing on discounted inventory. Financially, the company reported positive net income and maintains liquidity with a current ratio above 1.0 as of the end of 2025.

Scientific Industries, Inc. is a manufacturer and marketer of benchtop laboratory equipment and bioprocessing systems. The company operates two segments: Benchtop Laboratory Equipment, which includes balances, scales, pill counters, and moisture analyzers sold under the Torbal® and VIVID® brands; and Bioprocessing Systems, which offers smart sensor-based products and software analytics marketed under the DOTS brand. The company sold its Genie Division in August 2025 but continues to operate the Torbal Division. Bioprocessing Systems operations are based primarily in Germany, with a direct sales force and distributor network. The company holds patents for key products and invests heavily in product development. Major customers and vendors represent significant portions of sales and purchases. The company faces competition from larger companies and operates in a niche market with limited backlog and no material seasonality.

Callan JMB Inc. operates as a vertically integrated logistics and fulfillment company focused on thermal management logistics solutions for the life sciences sector. Its services include emergency preparedness and response, specialty temperature-regulating reusable packaging, fulfillment services, and advanced monitoring technology (Sentry) to ensure the integrity of temperature-sensitive biological products. The company leverages proprietary technology and a broad North American footprint to serve a diversified customer base, including government agencies and Fortune 500 firms. Callan JMB completed its IPO in 2025 and continues to expand through strategic contracts and joint ventures, emphasizing environmental sustainability and technological innovation.

American Rebel Holdings Inc is a lifestyle brand focused on American patriotism, offering products including branded safes, personal security items, apparel, and a light beer brand. The company acquired Champion Safe Company in 2022, significantly expanding its safe manufacturing and sales operations. Its safes are primarily made with U.S.-sourced steel and are marketed for home and personal security. The company launched American Rebel Light Beer in September 2024, distributing it across multiple U.S. states through partnerships and e-commerce. American Rebel also pursues brand licensing opportunities and has made strategic minority investments to broaden its product portfolio and operational reach. The company emphasizes a patriotic brand identity and engages in marketing through motorsports, music festivals, and retail partnerships. Financially, the company reported a net loss and limited liquidity as of the end of 2025, with ongoing capital needs to support its growth strategy.

CPI Aerostructures, Inc. (CPI Aero) is a U.S.-based aerospace and defense manufacturer with over 45 years of experience. The company produces structural assemblies, integrated systems, and provides kitting and MRO services primarily for military and commercial aerospace customers. CPI Aero serves as a prime contractor to the U.S. Department of Defense and as a Tier 1 subcontractor to leading defense primes such as Lockheed Martin, RTX Corporation, and Northrop Grumman. Its product offerings span aerostructures (wing structures, engine inlets, doors), aerosystems (pod structures, radar housings), complex tube bending, specialty welding, and electrical cables and harnesses. The company emphasizes build-to-print manufacturing and engineering services, supporting customer programs with program management, supply chain management, and quality assurance. CPI Aero competes with larger Tier 1 suppliers and internal manufacturing arms of customers, leveraging its combination of large contractor capabilities and small company flexibility. The company maintains a diversified customer base with approximately 80% of revenue from defense prime subcontracts, 9% from commercial contracts, and 11% from direct government sales. CPI Aero's backlog stood at approximately $504.5 million at the end of 2025, reflecting a mix of funded and unfunded contracts. The company reported a net loss for fiscal 2025 and maintains a current ratio of 1.89, indicating liquidity to meet short-term obligations [S1][S2].

TMC the metals Co Inc. develops polymetallic nodules from the deep seabed in the Clarion Clipperton Zone, a large area in the Eastern Pacific Ocean rich in critical metals such as nickel, copper, cobalt, manganese, and rare earth elements. The company aims to create a sustainable metal supply chain to meet rising demand in strategic sectors including semiconductors, energy, defense, and batteries. TMC is advancing its projects through regulatory pathways under the U.S. Deep Seabed Hard Mineral Resources Act and maintains contracts with the International Seabed Authority. It has established strategic partnerships with leading offshore engineering, smelting, refining, and technology companies to develop commercial-scale collection and processing systems. The company is developing a near-zero solid waste processing flowsheet and is exploring onshore processing facilities in the United States. TMC reported modest revenue and significant net losses as it remains in the development phase, with liquidity supported by cash reserves. The company faces risks related to regulatory approvals, financing, operational execution, market acceptance of novel products, and legal proceedings.

Copley Acquisition Corp is a Cayman Islands exempted company formed as a special purpose acquisition company (SPAC) with the objective of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. The company focuses on technology and lifestyle sectors, targeting businesses primarily in the Asia Pacific region (excluding the PRC) and North America. It completed its initial public offering in May 2025, raising gross proceeds of $172.5 million, which are held in a trust account to fund a future business combination. The company has not yet identified or entered into a definitive agreement with any target business. Its management team has significant experience in financial services and technology industries and leverages a broad network for deal sourcing. The company is subject to NYSE rules requiring the initial business combination to have a fair market value of at least 80% of the trust account balance. If it fails to complete a business combination within the prescribed timeframe (up to 24 months), it will liquidate and redeem public shares.

Afya Ltd is a Brazilian education company focused on medical and health-related education services. It operates through three segments: Undergraduate education offering medical and health science courses; Continuing Education providing medical specialization and residency preparation via digital and in-person formats; and Medical Practice Solutions delivering clinical management and decision support services to healthcare professionals. The company generates revenue primarily from tuition fees, digital content subscriptions, and related educational services. Afya has expanded through acquisitions and organic growth, increasing its student base and service offerings. The company reported steady revenue and net income growth in 2025, supported by operational efficiencies and increased enrollment. It maintains a strong liquidity position and invests in capital expenditures to support growth and infrastructure.

NewGenIvf Group Ltd operates assisted reproductive services (ARS) clinics primarily in Asia Pacific, including Thailand, Cambodia, and Kyrgyzstan. The company provides IVF treatment services and fertility referral services, with a strategic focus on expanding its client base and service offerings across the region. Revenue decreased from $5.4 million in 2024 to $4.7 million in 2025, with IVF treatment revenue declining and fertility referral services emerging as a new revenue stream. The company reported net income of $9.7 million in 2025, influenced by a significant bargain purchase gain from acquisitions. NewGenIvf is also pursuing diversification through investments in digital assets and real estate, including a $45 million investment in UAE real estate and a $30 million investment in Solana blockchain technology. The company has undertaken multiple reverse stock splits to consolidate shares and has a share repurchase program. It faces risks related to regulatory environments, international travel conditions affecting client access, and market liquidity of digital assets.